Immunohistochemical overexpression of her2/neu in breast carcinomas is described as a predictor of response to alkylating agents or anthracycline therapies; however, its definite role in primary eas of breast remains to be explored 22. The gene discussed is ERBB2; the disease is breast carcinoma.